Livzon Pharmaceutical Group Inc.
000513
Rank in Stocks
#4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Share Price
$3.90
Market Cap
$3.17B
Change (1 day)
-3.49%
Change (1 year)
-25.88%
Country
CN
Trade Livzon Pharmaceutical Group Inc. (000513)
Category
Healthcare
P/B ratio for Livzon Pharmaceutical Group Inc. (000513)
P/B ratio as of October 2026 TTM: 1.73
According to Livzon Pharmaceutical Group Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 1.73. At the end of 2024 the company had a P/B ratio of 2.52.
P/B ratio history for Livzon Pharmaceutical Group Inc. from 2001 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 1.73 | -20.71% |
| 2025 | 2.18 | -13.65% |
| 2024 | 2.52 | 8.22% |
| 2023 | 2.33 | 6.50% |
| 2022 | 2.19 | -24.26% |
| 2021 | 2.89 | -7.73% |
| 2020 | 3.13 | 11.01% |
| 2019 | 2.82 | 76.02% |
| 2018 | 1.60 | -53.23% |
| 2017 | 3.43 | -5.60% |
| 2016 | 3.63 | -28.53% |
| 2015 | 5.08 | 28.20% |
| 2014 | 3.96 | 15.88% |
| 2013 | 3.42 | -0.27% |
| 2012 | 3.43 | 61.80% |
| 2011 | 2.12 | -58.95% |
| 2010 | 5.16 | -6.32% |
| 2009 | 5.51 | 83.92% |
| 2008 | 3.00 | -55.83% |
| 2007 | 6.78 | 391.14% |
| 2006 | 1.38 | 30.20% |
| 2005 | 1.06 | -39.40% |
| 2004 | 1.75 | -1.89% |
| 2003 | 1.78 | -31.10% |
| 2002 | 2.59 | -9.03% |
| 2001 | 2.85 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 1.9834 | 14.75% |
DE
|
|
| 2.1139 | 22.30% |
DE
|
|
| 1.3124 | -24.07% |
JP
|
|
| 6.3468 | 267.19% |
CH
|
|
| 5.0287 | 190.93% |
IN
|
